Humoral response to the BBIBP-CorV vaccine over time in healthcare workers with or without exposure to SARS-CoV-2

  1. María Noel Badano
  2. Florencia Sabbione
  3. Irene Keitelman
  4. Matias Pereson
  5. Natalia Aloisi
  6. Ana Colado
  7. María Victoria Ramos
  8. Juan Manuel Ortiz Wilczyñski
  9. Roberto Gabriel Pozner
  10. Luis Castillo
  11. Georgina Wigdorovitz
  12. María Marta E.de Bracco
  13. Susana Fink
  14. Roberto Chuit
  15. Patricia Baré

Reviewed by

Read the full article See related articles

Discuss this preprint

Start a discussion What are Sciety discussions?

Listed in

Log in to save this article

Abstract

No abstract available

Article activity feed

  1. Version published to 10.1016/j.molimm.2022.01.009
  2. ScreenIT

    SciScore for 10.1101/2021.10.02.21264432: (What is this?)

    Please note, not all rigor criteria are appropriate for all manuscripts.

    Table 1: Rigor

    EthicsIRB: This study was approved by the local Ethics Committee of the Academia Nacional de Medicina and written informed consent was obtained from each participant.
    Consent: This study was approved by the local Ethics Committee of the Academia Nacional de Medicina and written informed consent was obtained from each participant.
    Sex as a biological variablenot detected.
    Randomizationnot detected.
    Blindingnot detected.
    Power Analysisnot detected.

    Table 2: Resources

    Antibodies
    SentencesResources
    SARS-CoV-2 antibody ELISA: SARS-CoV-2 spike-specific IgG antibodies were measured using the ELISA test COVIDAR according to the manufacturer’s instructions (Laboratorios Lemos S.R.L, Buenos Aires, Argentina) [5].
    spike-specific IgG
    suggested: None
    Antibody concentrations to SARS-CoV-2 spike protein expressed as International Units/mL (IU/mL) were determined by constructing a calibration curve with serial dilutions of the standard included in the immunoassay kit (400 IU/ml, reactive human serum adjusted to WHO First International Standard for human immunoglobulin against SARS-CoV-2, NIBSC Code 20/136, version 2.0 of 12/17 / 2020).
    SARS-CoV-2
    suggested: None
    For each time point studied, geometric mean concentrations (GMC) of anti-spike-specific antibodies levels with 95% CI were calculated.
    anti-spike-specific
    suggested: None
    Software and Algorithms
    SentencesResources
    All data analyses were performed using the GraphPad 9.1.2 Prism software (GraphPad Software, San Diego, CA, USA).
    GraphPad
    suggested: (GraphPad Prism, RRID:SCR_002798)

    Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).

    Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:
    This study has some limitations. Most of the unexposed subjects have unknown serostatus prior to vaccination. However, the low seroconversion rate after the first dose and the abrupt decline in antibody levels 3 months after the second dose, strongly suggest that they were seronegative at baseline. Antibody neutralization assays were not performed and therefore should be done to estimate long-term protection after BBIBP-CorV vaccine. Despite the low number of SARS-CoV-2 exposed subjects to draw strong conclusions, the same tendency for other vaccine platforms was observed, showing that robust antibody responses are elicited after one shot of BBIBP-CorV vaccine in individuals with prior infection. In summary, in the present study we quantified anti-spike antibodies over time after vaccination with BBIBP-CorV vaccine in terms of IU/ml, allowing assays from different laboratories to be compared. Despite the 100% seroconversion rate achieved after the second dose, a decline in anti-spike antibody levels was seen 3 months after dose 2. Several factors like sex, age and exposure to SARS-CoV-2 seem to influence the magnitude of this humoral response, as the highest antibody concentrations in unexposed subjects were seen in younger subjects and women, and the combination of exposure to SARS-CoV-2 virus plus vaccination, whatever the sequence of the events is, produces a sharp increase in antibody levels. Overall, our results suggest that the evaluation of the humoral response over ti...

    Results from TrialIdentifier: No clinical trial numbers were referenced.

    Results from Barzooka: We did not find any issues relating to the usage of bar graphs.

    Results from JetFighter: We did not find any issues relating to colormaps.

    Results from rtransparent:
    • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
    • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
    • No protocol registration statement was detected.

    Results from scite Reference Check: We found no unreliable references.

    About SciScore

    SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

  3. Version published to 10.1101/2021.10.02.21264432 on medRxiv